Home

John E Bishop

CIK 1308911 · See Remarks · last filed 2026-05-22

John E Bishop is a corporate insider who has filed 134 SEC Form 4 insider transactions across 4 companies since 2007. The most recent filing shows the insider sold $14.5K of ARDX on May 22, 2026. Across all open-market trades the lifetime net is −$6.4M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $1.3M across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$1.35M

Companies

4

Total Filings

134

Lifetime Open-Market Net

-$6.43M

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
ARDX See Remarks 336,845 $4.00 $1.35M -$33.0K 3 2026-05-22
Lyra Therapeutics, Inc. (LYRA) Delisted Chief Technology Officer — $0.70 — $0 2 2024-02-01
Forma Therapeutics Holdings, Inc. (FMTX) Delisted SVP, Chief Technology Officer 0 $20.01 $0 $0 3 2022-10-14
MOMENTA PHARMACEUTICALS INC (MNTA) Delisted Senior VP, Pharmaceutical Scie 157,640 — — -$6.40M 124 2016-05-23

Recent Filings

134 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-05-22 ARDX Sell (S) −2,306 -$14.5K EDGAR
2026-05-19 ARDX Notice (144) −3,700 -$23.1K EDGAR
2026-02-23 ARDX Sell (S) −3,179 -$18.6K EDGAR
2026-02-20 ARDX Notice (144) −3,700 -$21.2K EDGAR
2026-01-26 ARDX Grant (A) +124,330 $0 EDGAR
2024-02-01 Lyra Therapeutics, Inc. (LYRA) Delisted Grant (A) — $0 EDGAR
2023-02-28 Lyra Therapeutics, Inc. (LYRA) Delisted Grant (A) — $0 EDGAR
2022-10-14 Forma Therapeutics Holdings, Inc. (FMTX) Delisted Mixed −47,950 $0 EDGAR
2022-03-02 Forma Therapeutics Holdings, Inc. (FMTX) Delisted Grant (A) +25,950 $0 EDGAR
2021-06-15 Forma Therapeutics Holdings, Inc. (FMTX) Delisted Grant (A) +22,000 $0 EDGAR
Showing 1–10 of 134
Page 1 of 14
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.